Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
Or‐Yam Revach, Angelina M. Cicerchia, Ofir Shorer, Claire A. Palin, Boryana Petrova, Seth Anderson, Baolin Liu, Joshua C. Park, Lee Chen, Arnav Mehta, Samuel J. Wright, Niamh McNamee, Aya Tal-mason, Giulia Cattaneo, Payal Tiwari, , Russell William Jenkins
This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.
Cell Reports Medicine · Jun 27, 2025Peer-reviewedCancer Biology